ascentage.com - AAPGV Company Value to Revenue

Official company branding of ascentage.com (AAPGV)

Ascentage Pharma Group is a reputable developer of targeted oncology therapies creating innovative treatments for resistant leukemias. Software robots are currently being implemented to process clinical data arrays. The company's enterprise value based on revenue, excluding debt, reflects market dynamics where the value of 12973.75 corresponds to the current metric. Brand equity is based on partner payments and the commercialization of drugs in the US and China.

ascentage.com (AAPGV): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Ascentage Pharma Group International - analytical breakdowns and key metrics (AAPGV)

Fundamental company valuation:AAPGV Ascentage Pharma Group
Manufactured products of Ascentage Pharma

The selection of high-quality issuers is based on comparing the market value of a business with its actual ability to generate income. The EV/Sales ratio measures the enterprise value relative to sales volume, excluding the impact of debt load, which allows for an assessment of the monetization efficiency of Ascentage Pharma Group (AAPGV) patents for the drug Lisoftus and the potential of their targeted developments through the price action on this chart.

Competitor analysis for Ascentage Pharma Group

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|XLO: EV/Sales Multiple|Enochian BioSciences (RENB) - EV/Sales Multiple|Company Value to Revenue MURA|Kairos Pharma Ltd - Enterprise Value to Sales Volume|EV/Sales Multiple OKUR|CytoMed Therapeutics Limited (GDTC) - Enterprise Value-to-Sales Ratio|EV/Sales Multiple CRIS (Curis, Inc.)|APLM: Company Value to Revenue Ratio|Tharimmune Corporation - EV/Sales Multiple|ADVB: Enterprise Value-to-Revenue Ratio|GNPX: EV/Sales Multiple|CLDI (Calidi Biotherapeutics Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Sunshine Biopharma, Inc.|EV/Sales Multiple xeneticbio.com|Enterprise Value-to-Revenue Ratio Salarius (SLRX)|Company Value to Revenue Purple Biotech PPBT|Enterprise Value-to-Revenue Ratio American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Enterprise Value-to-Revenue Multiple|Checkpoint Therapeutics Inc. - EV/Sales Multiple|Business Value to Revenue ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Company Value to Revenue|Ikena Oncology, Inc. - Business Value to Revenue|Company Value to Revenue NTBL|VIRX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio MorphoSys Corporation (MOR)|NAYA - Enterprise Value-to-Revenue Multiple